183 related articles for article (PubMed ID: 38528641)
21. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
23. DNA methylation-mediated silencing of microRNA-204 enhances T cell acute lymphoblastic leukemia by up-regulating MMP-2 and MMP-9 via NF-κB.
Lin C; Chen D; Xiao T; Lin D; Lin D; Lin L; Zhu H; Xu J; Huang W; Yang T
J Cell Mol Med; 2021 Mar; 25(5):2365-2376. PubMed ID: 33566449
[TBL] [Abstract][Full Text] [Related]
24. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
25. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
[TBL] [Abstract][Full Text] [Related]
26. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Yan-Fang T; Jian N; Jun L; Na W; Pei-Fang X; Wen-Li Z; Dong W; Li P; Jian W; Xing F; Jian P
BMC Med Genet; 2013 Jul; 14():74. PubMed ID: 23870168
[TBL] [Abstract][Full Text] [Related]
27. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.
Shah K; Al Ashiri L; Nasimian A; Ahmed M; Kazi JU
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902436
[TBL] [Abstract][Full Text] [Related]
29. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
31.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.
Fischer MA; Song Y; Arrate MP; Gbyli R; Villaume MT; Smith BN; Childress MA; Stricker TP; Halene S; Savona MR
Haematologica; 2023 Feb; 108(2):522-531. PubMed ID: 35979721
[TBL] [Abstract][Full Text] [Related]
33. Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis.
Huang J; Jin S; Guo R; Wu W; Yang C; Qin Y; Chen Q; He X; Qu J; Yang Z
RNA; 2024 Mar; 30(4):435-447. PubMed ID: 38296629
[TBL] [Abstract][Full Text] [Related]
34. Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane.
Liang B; Jiang D; Pan L; Xiong F; Feng S; Wu S; Ye H; Yu Z; Shi C; Gao S
Acta Biomater; 2022 Jun; 145():246-259. PubMed ID: 35405327
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
36. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
37. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
Waclawiczek A; Leppä AM; Renders S; Stumpf K; Reyneri C; Betz B; Janssen M; Shahswar R; Donato E; Karpova D; Thiel V; Unglaub JM; Grabowski S; Gryzik S; Vierbaum L; Schlenk RF; Röllig C; Hundemer M; Pabst C; Heuser M; Raffel S; Müller-Tidow C; Sauer T; Trumpp A
Cancer Discov; 2023 Jun; 13(6):1408-1427. PubMed ID: 36892565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]